Generate Biomedicines
Generative biology platform for AI-designed protein therapeutics
Generate Biomedicines is a serious bet on AI-designed protein therapeutics, backed by 42,000+ tested proteins and a Phase 3 asset. The integrated compute-biology loop is a genuine differentiator, but the model is high-risk and capital-intensive. Pick it for transformative partnerships, not quick wins.
Verified 5d ago · liveness 50/100 · cite: rightaichoice.com/tools/generate-biomedicines
- Pharma companies seeking AI-designed novel antibodies or proteins
- Investors looking for a clinical-stage generative biology platform
- Research collaborations requiring de novo protein design capabilities
- Severe asthma patients (via GB-0895 in Phase 3 trials)
- Companies needing off-the-shelf biologics or generic discovery tools
- Startups wanting a low-cost AI drug discovery solution
- Drug developers focused on small molecules or gene therapies
We scan live Reddit threads, YouTube comments, X posts, G2 reviews and other communities — and hand you an honest verdict in under a minute.
- Honest verdict, not marketing
- Real pros & cons from real users
- Attributed quotes with receipts
3 free scans · no card needed
Skip Generate Biomedicines if you need an off-the-shelf AI drug discovery tool with a public API or self-service access—this platform is only available via partnerships and licensing, and its pipeline is still in early stages.
Access to the Generate Platform requires a partnership or licensing agreement, with pricing and specific capabilities disclosed only under NDA—expect significant upfront investment and long-term commitment.
Generate Biomedicines operates on a partnership/licensing model rather than public pricing—expect enterprise-level, custom contracts suited for large pharma and deep-pocketed investors, with costs likely far higher than typical SaaS drug discovery tools.
In short
Generate Biomedicines — Generative biology platform for AI-designed protein therapeutics. Best for Pharma companies seeking AI-designed novel antibodies or proteins, Investors looking for a clinical-stage generative biology platform, Research collaborations requiring de novo protein design capabilities. Contact Sales pricing.
What's new in Generate Biomedicines
Checked 5 days agoAcross the latest 2 updates: 1 launch and 1 news mention.
Forbes Feature: Generative Biology Is Rewriting The Rules Of Drug Discovery
Highlights how generative biology is transforming drug discovery, showcasing the platform's impact.
Peer-Reviewed First-in-Human Results for GB-0669
Published first-in-human data for AI-designed antibody GB-0669, demonstrating safety and efficacy signals.
Viability Score
How well maintained and how widely used is Generate Biomedicines? Built from what the vendor actually publishes (docs, changelog, tutorials, integrations, pricing), whether the site is live, and how much real users discuss it. How we calculate this
Last calculated: September 2026
How we score →Key Features
- Generative protein design with machine learning
- Real-time feedback loop between computation and biology
- Multi-modal therapeutic creation (antibodies, enzymes, cytokines)
- De novo antibody discovery against tough targets
- Long-acting biologic engineering (e.g., GB-0895)
- Protein half-life redesign
- 42,000+ proteins generated, built, and tested
- GB-0895 anti-TSLP antibody in Phase 3 (SOLAIRIA)
- Peer-reviewed first-in-human results for GB-0669
- GB-4362 advancing into clinical development
- Human insight embedded at every layer
- 140k+ square feet of lab space (Boynton Yards, Andover)
- Targeted drug delivery protein design
- Integrated discovery-to-clinical pipeline
About Generate Biomedicines
Generate Biomedicines is a clinical-stage therapeutics company pioneering generative biology to design novel protein medicines on demand. Its Generate Platform combines machine learning with biological engineering, where the system learns the generalizable rules nature uses to encode function, then applies those rules to create new proteins across multiple therapeutic modalities. This is not a handoff between code and bench; it is a living feedback loop where experimentation continuously trains and refines the system in real time. The platform has studied millions of proteins and has generated, built, and tested over 42,000 proteins to date, with a goal to fundamentally change the way medicines are made. Its lead asset, GB-0895, a long-acting anti-TSLP antibody for severe asthma, is currently in global Phase 3 studies under the SOLAIRIA trial. Recent first-in-human results for GB-0669, an AI-designed antibody, were peer-reviewed and published, reinforcing the platform's ability to go after tough viral targets. Generate also announced advances in GB-4362, a candidate designed to go beyond tolerability limits, now entering clinical development. The company reported Q2 2026 financial results and was featured in Forbes for rewriting the rules of drug discovery. Its physical footprint has expanded to over 140,000 square feet across Boynton Yards and Andover. Generate Biomedicines does not offer a public API or self-service platform; access requires partnership or licensing. It is built for pharma partners and investors focused on long-term therapeutic innovation, but not for those seeking off-the-shelf tools or small-molecule-focused workflows.
Behind the Verdict
Generate Biomedicines is a serious bet on AI-designed protein therapeutics, backed by 42,000+ tested proteins and a Phase 3 asset. The integrated compute-biology loop is a genuine differentiator, but the model is high-risk and capital-intensive. Pick it for transformative partnerships, not quick wins.
Researching Generate Biomedicines? Get your full AI stack in 60 seconds.
Free, no signup — tell us your goal and get tools matched to your budget & existing stack.
Real-world workflow fit
Concrete scenarios for the personas Generate Biomedicines actually fits — and what changes day-one when you adopt it.
You need novel antibodies for a difficult target. Engage Generate for a partnership to leverage their platform for de novo design, then iterate with their compute-biology loop until you have a lead.
Outcome: Access a pipeline of AI-designed candidates with validation data, potentially accelerating your discovery timeline.
You're evaluating a clinical-stage biotech. Analyze Generate's platform capabilities and pipeline progress, including GB-0895's Phase 3 status and peer-reviewed results.
Outcome: Make an informed investment decision based on the platform's technical depth and clinical milestones.
You want to explore generative biology for a specific disease. Collaborate with Generate's scientists to design proteins under their platform, with shared IP agreements.
Outcome: Co-develop novel therapeutics with access to their 42,000+ protein dataset and integrated discovery pipeline.
Use Cases
- Design novel antibodies targeting specific disease antigens for therapeutic development.
- Engineer enzymes with enhanced stability or activity for industrial or medical applications.
- Generate cytokine variants with reduced side effects for cancer immunotherapy.
- Develop long-acting biologics by redesigning protein half-life properties.
- Create de novo proteins for targeted drug delivery systems.
Models Under the Hood
as of 2026-08-30
Limitations
- Generate Biomedicines does not offer a public API or self-service platform; access requires a partnership or licensing agreement.
- The platform is designed for internal use by their scientists and collaborators, and is not available as a standalone product.
- Pricing and specific capabilities are only disclosed under NDA.
as of 2026-08-29
Verification history
We have re-verified Generate Biomedicines 16 times since . Each pass re-reads the vendor's own pages and re-checks every listed field against that evidence; passes where nothing had changed are marked as such.
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
Showing the 6 most recent of 16 verification passes.
Free to cite with attribution — this page re-verifies continuously.
Where the pricing makes sense
The company stage and team size where Generate Biomedicines's pricing actually pencils out — and where peers do it cheaper.
Generate Biomedicines operates on a partnership/licensing model rather than public pricing—expect enterprise-level, custom contracts suited for large pharma and deep-pocketed investors, with costs likely far higher than typical SaaS drug discovery tools.
Setup time & first value
How long it actually takes to get something useful out of Generate Biomedicines — broken out by persona, not the marketing-page minute.
For pharma partners, initial setup could take weeks to months due to NDA processes and scientific alignment. Investors can get an overview in days, but research collaborations require extended onboarding for data sharing and platform access.
Resources & Guides
Tutorials & Learning
Official links
Tools that pair well with Generate Biomedicines
Common stack mates teams adopt alongside Generate Biomedicines, with the specific reason each pairing earns its keep.
Pando Bioscience
Generative AI-designed enzymes for pharma manufacturing and life science tools
Insilico Medicine
End-to-end generative AI drug discovery platform from target ID to clinical trials, validated by a Phase III pipeline.
Iktos
Generative AI and robotics for autonomous drug discovery, compressing the DMTA cycle to under two years.
Alternatives to Generate Biomedicines
View allPando Bioscience
Generative AI-designed enzymes for pharma manufacturing and life science tools
Insilico Medicine
End-to-end generative AI drug discovery platform from target ID to clinical trials, validated by a Phase III pipeline.
Frequently Asked Questions
Categories
Topics
Used Generate Biomedicines? Help shape our editorial sentiment research.